3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Osteoporosis
4
Prostatic Neoplasms
3
Breast Neoplasms
3
Vitamin D Deficiency
2
Polycystic Ovary Syndrome
2
Neoplasms
2
Cardiovascular Diseases
2
Vitamin D3
1
Neuroma
1
Melanoma, Cutaneous Malignant
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Locally Advanced Breast Cancer and Large Operable Breast Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Insulin Resistance
1
Fractures, Bone
1
Colorectal Adenocarcinoma
1
Interventions
Rituximab
67
Cyclophosphamide
39
Vincristine
33
Prednisone
31
Doxorubicin
25
Lenalidomide
18
Radiotherapy
16
Bendamustine Hydrochloride
14
Peripheral Blood Stem Cell Transplantation
10
Filgrastim
10
Etoposide
10
Prednisolone
8
tofacitinib
7
obinutuzumab
6
ibritumomab tiuxetan
6
fludarabine
6
VAP-cyclo protocol
6
Mitoxantrone
6
Methylprednisolone
6
Deoxycholic Acid
6
Cytarabine
6
Melphalan
5
Dexamethasone
5
Carmustine
5
ibrutinib
4
fludarabine phosphate
4
R-CHOP protocol
4
Methotrexate
4
Interferon-alpha
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Follicular
×
Cholecalciferol
×
Clear all
NCT03078855
2024-09-04
ILyAD
University of Rochester
Phase 3
Completed
211 enrolled
13 charts